Clinical observation of albumin-bound paclitaxel plus bevacizumab as second-line therapy in patients with advanced pancreatic cancer
10.3760/cma.j.issn.1673-422X.2014.08.019
- VernacularTitle:白蛋白结合型紫杉醇联合贝伐珠单抗二线治疗晚期胰腺癌的临床观察
- Author:
Shaojiang HUANG
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Albumin-bound paclitaxel;
Bevacizumab
- From:
Journal of International Oncology
2014;(8):620-623
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy,adverse reaction and survival condition of albumin-bound paclitaxel combined with bevacizumab as second-line therapy in patients with advanced pancreatic cancer. Methods Twenty-seven cases of advanced pancreatic cancer were enrolled to receive albumin-bound paclitaxel combined with bevacizumab regimen. The dose of the drugs was as follows:albumin-bound paclitaxel 130 mg/ m2 ,d1,bevacizumab 7. 5 mg/ m2 ,d1. Twenty-one days were a cycle for each regimen,and the least chemotherapy cycle was 2. The adverse reactions were evaluated for each cycle and the objective response was evaluated for 2 cycles. Results The 27 patients could be evaluated. None was in complete remission,2 cases were in partial remission,14 cases were in stabilization,11 cases were in progress. The response rate(RR) was 7. 41% ,and the disease control rate(DCR)was 59. 26% . The median progress free survival(PFS)was 4 months(95% CI:3. 004-4. 996 months),and the median overall survival(OS)was 8 months(95% CI:5. 900-10. 100 months). The main adverse reactions included myelosuppression,gastrointestinal reaction, fatigue,lipsotrichia,erythra,peripheral neurotoxicity,etc,most of which were 1-2 grade. The adverse effect was well tolerated,and there was no treatment-related death. Conclusion The albumin-bound paclitaxel com-bined with bevacizumab as second-line therapy in patients with advanced pancreatic cancer shows slow progress and low adverse effect and needs further study.
